Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain's $300 million financing round, the ...

Bain Capital and Bristol Myers Squibb are providing financial and scientific support to a new startup working on autoimmune ...

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...

Bristol Myers Squibb and Bain Capital are forming a new biopharmaceutical company focused on therapies for autoimmune diseases. The new company will be created with $300 million in financing led by ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 assets and $300M funding. Read more here.

Bristol Myers Squibb and Bain Capital are forming a new biopharmaceutical company focused on therapies for autoimmune diseases. The new company will be created with $300 million in financing led ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Bristol Myers Squibb (NYSE:BMY) and Bain Capital have announced the establishment of a new independent biopharmaceutical company dedicated to creating treatments for autoimmune diseases. The new ...

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

Discover Bristol-Myers Squibb's Q2 2025 earnings insights: 17% growth, new partnerships, and raised guidance signal strong performance and a ...